NVO vs PFE

Novo Nordisk A/S and Pfizer, both Healthcare

Novo Nordisk A/S is the larger company at $191B against $144B. Over the past year PFE returned +24% against +1.5% for NVO. Ryufin's sector-relative Smart Score puts NVO ahead, 9/10 against 7/10.

Novo Nordisk A/S and Pfizercompared on valuation, return and Ryufin’s Smart Score
Figure	NVO	PFE
Last close	$47.19	$28.32
Market cap	$191B	$144B
Trailing P/Elower is cheaper for the same earnings, not automatically better	n/a	37.3
Dividend yield	n/a	6.1%
1-year return	+1.5%	+24%
5-year return	+13%	-15%
Ryufin Smart Scoresector-relative, 1–10	9/10	7/10

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

Novo Nordisk A/S

NVO overview revenue and segments valuation

Pfizer

Revenue of $15B in Q2 2026, net income null. Its largest reported line is Eliquis, 15% of the disclosed total.

PFE overview revenue and segments valuation

Open these two in the interactive comparison to add more names, change the period or read the correlation.